Endocrine events that signal less exposure to estradiol, such as shorter reproductive span, younger age at menopause, and hysterectomy, increase dementia risk.
TherapeuticsMD announced the launch of Bijuva (estradiol and progesterone) capsules for use in women with a uterus for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.
Researchers have identified reproductive risk factors associated with an increased risk for total knee replacement in women with severe knee osteoarthritis.
The expanded approval was based on safety and efficacy data from a confirmatory Phase 3 randomized, double-blind, placebo-controlled multicenter study evaluating Osphena in patients with moderate to severe vaginal dryness.
Initiation and continuation trends in menopausal hormone therapy may have been influenced by the premature cessation of the 2002 Women’s Health Initiative trial, which was halted due to safety concerns.
A study was conducted to assess the safety, tolerability, and efficacy of methyl estradiolpropanoate, a topical soft estrogen cosmeceutical for the treatment of estrogen-deficient skin.
Oral preparations of hormone replacement therapy for the treatment of menopausal symptoms are associated with a greater risk for VTE compared with transdermal formulations.
